Inhibition of β-catenin translocation in rodent colorectal tumors: A novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer

Digestive Diseases and Sciences

Volumn 46, Issue 11, 2001, Pages 2314-2321

  Brown, W A ^a   Skinner, S A ^a   Vogiagis, D ^a   O'Brien, P E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Apoptosis; Colorectal cancer; Immunohistochemistry; Nonsteroidal antiinflammatory drugs; catenin

Indexed keywords

BETA CATENIN; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG EFFECT; GENE TARGETING; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; STAINING; TARGET CELL;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BETA CATENIN; CADHERINS; CARCINOGENS; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; IMMUNOHISTOCHEMISTRY; PROTEIN TRANSPORT; RATS; TRANS-ACTIVATORS;

EID: 0034755368     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012326525692     Document Type: Article

References (50)

1. Colorectal cancer risk, chronic illnesses, operations and medications: Case control results from the Melbourne Colorectal Cancer Study
2. Risk factors for fatal colon cancer in a large prospective study
3. Aspirin use and risk of fatal cancer
4. Aspirin and the risk of colorectal cancer in women
5. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat
6. Sulindac and indomethacin inhibit formation of aberant crypt foci in the colons of dimethyl hydrazine treated rats
7. Towards a better aspirin
8. NSAIDs, COX-2 inhibitors, and the gut
9. Sulindac causes rapid regression of pre-existing tumours in Min/+ mice independent of prostaglandin biosynthesis
10. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat
11. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis
12. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
13. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
14. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumours
15. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
16. Chemoprevention of colorectal cancer - A comparative study of efficacy and gastrotoxicity of NSAIDs
17. Suppression of intestinal polyposis in APC-716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
18. A genetic model for colorectal tumorigenesis
19. Mutational analysis of the APC/β-Catenin/Tcf pathway in colorectal cancer
20. The gatekeeper has many keys: Dissecting the function of the APC gene
21. Activation of the β-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations
22. β-Catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas
23. Intracellular distribution of B-catenin in colorectal adenomas, carcinomas and Peutz-Jeghers polyps
24. Binding of GSK3B to the APC-B-catenin complex and regulation of complex assembly
25. Association of the APC gene product with β-catenin
26. Functional interaction of β-catenin with the transcription factor LEF-1
27. Activation of βcatenin-Tcf signaling in colon cancer by mutations in β-catenin or APC
28. The multi-talented β-catenin makes its first appearance
29. Synergy between tumour suppressor APC and the βcatenin-Tcf4 target Tcf1
30. Identification of c-MYC as a target of the APC pathway
31. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway
32. Transcriptional activation of cyclooxygenase-2 in Wnt-1 transformed mouse mammary epithelial cells
33. The metalloproteinase matrilysin is a target of B-catenin transactivation in intestinal tumors
34. AOM-induced mouse colon tumors do not express full-length APC protein
35. β-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumours
36. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
37. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
38. COX-2 inhibitors - A new generation of safer NSAIDs?
39. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase
40. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells
41. Cyclooxygenase-2 inhibitors - A new class of anti-inflammatory agents that spare the gastrointestinal tract
42. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
43. Nonsteroidal antiinflammatory drugs with varying activity against either cyclooxygenase-1 or cyclooxygenase-2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation
44. NSAIDs with varying activity against the two cyclooxygenase isoforms induce apoptosis and reduce proliferation in a rodent colon cancer model
45. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction
46. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta
47. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
48. Sulindac sulfone modulates the expression and cellular location of β-catenin in human colon carcinoma cells
49. Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice
50. Nucleocytoplasmic transport: Signals, mechanisms and regulation